Korea Investment CORP Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN

Korea Investment CORP bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 74,955 shares of the biopharmaceutical company's stock, valued at approximately $46,737,000. Korea Investment CORP owned approximately 0.07% of Regeneron Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of REGN. WPG Advisers LLC boosted its position in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 25 shares in the last quarter. Western Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $26,000. SHP Wealth Management acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $26,000. Titan Wealth CI Ltd acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $29,000. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $31,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on REGN. Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a "buy" rating in a research note on Monday, August 3rd. Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an "equal weight" rating in a research report on Friday, July 31st. Truist Financial increased their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a "buy" rating in a report on Friday, July 31st. Benchmark upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $185.00 target price on the stock in a research report on Tuesday, July 7th. Finally, Canaccord Genuity Group cut their target price on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a "buy" rating for the company in a research note on Tuesday, May 19th. Sixteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $801.70.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Approval was supported by the Phase 3 OPTIMA trial, which showed a 90% or greater reduction in new lesions at 56 weeks. As the first approved treatment demonstrating this benefit in FOP, Pasatru could expand Regeneron’s rare-disease portfolio and create a new revenue stream. Regeneron to challenge Ipsen as FDA clears bone disease drug
• Positive Sentiment: Regeneron is also pursuing growth in obesity treatment. An update on its Phase 2 olatorepatide study has drawn investor attention because the program could give the company exposure to the large and rapidly expanding obesity-drug market, although clinical and commercial risks remain. Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside
• Neutral Sentiment: Multiple investor-law-firm notices announced a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to alleged disclosures about the Phase 3 Fianlimab-Libtayo melanoma trial; the notices themselves do not represent a new regulatory or operating development. Regeneron Investors Class Action Notice
• Negative Sentiment: The underlying litigation alleges that Regeneron misled investors about the viability and prospects of the Fianlimab-Libtayo trial, whose disappointing results reportedly caused a sharp share-price decline and an approximately $11 billion reduction in market value. Continued lawsuit announcements add reputational, legal-cost and potential financial-liability risks. Pomerantz Regeneron Investor Alert

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the firm's stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director directly owned 17,303 shares of the company's stock, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the business's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,400 shares of company stock valued at $1,090,030 over the last 90 days. 6.97% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $834.04 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The stock's 50 day simple moving average is $697.09 and its 200-day simple moving average is $716.73. The company has a market cap of $85.87 billion, a PE ratio of 20.61, a price-to-earnings-growth ratio of 1.42 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $847.00.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm had revenue of $4.29 billion during the quarter, compared to analysts' expectations of $3.82 billion. During the same period in the previous year, the business earned $12.81 earnings per share. The firm's revenue for the quarter was up 16.7% on a year-over-year basis. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals's payout ratio is 9.29%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source